Your browser is no longer supported. Please, upgrade your browser.
Settings
LPTX Leap Therapeutics, Inc. daily Stock Chart
LPTX [NASD]
Leap Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.45 Insider Own13.88% Shs Outstand17.51M Perf Week7.04%
Market Cap37.30M Forward P/E- EPS next Y-1.86 Insider Trans- Shs Float17.51M Perf Month29.09%
Income-42.50M PEG- EPS next Q-0.57 Inst Own39.80% Short Float2.14% Perf Quarter-26.80%
Sales- P/S- EPS this Y-65.20% Inst Trans-4.80% Short Ratio0.39 Perf Half Y-68.54%
Book/sh0.45 P/B4.73 EPS next Y21.80% ROA-96.60% Target Price12.83 Perf Year-74.46%
Cash/sh1.32 P/C1.61 EPS next 5Y-2.49% ROE-271.40% 52W Range1.35 - 10.25 Perf YTD6.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.22% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low57.78% ATR0.25
Employees21 Current Ratio4.00 Sales Q/Q- Oper. Margin- RSI (14)55.95 Volatility21.25% 11.93%
OptionableNo Debt/Eq0.00 EPS Q/Q37.80% Profit Margin- Rel Volume2.75 Prev Close2.33
ShortableYes LT Debt/Eq0.00 EarningsMar 15 Payout- Avg Volume972.32K Price2.13
Recom- SMA2025.55% SMA505.10% SMA200-59.23% Volume2,673,053 Change-8.58%
Mar-07-17Initiated Ladenburg Thalmann Buy $18
Mar-18-19 07:00AM  Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer PR Newswire
Mar-11-19 03:10PM  Four Tech Stocks Setting The Pace On Monday ACCESSWIRE
Mar-08-19 07:00AM  Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer PR Newswire +18.24%
Feb-05-19 06:15PM  Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of ... GuruFocus.com
01:29PM  Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities PR Newswire
Feb-01-19 09:28AM  Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants PR Newswire -23.08%
Jan-31-19 04:32PM  Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants PR Newswire -10.34%
Jan-30-19 08:30AM  2 Small-Cap Biotech Stocks That Are on My Radar TheStreet.com -13.69%
Jan-29-19 08:10AM  Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX Future Expectations, Projections Moving into 2019 GlobeNewswire -8.70%
Jan-14-19 07:00AM  Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer PR Newswire
Dec-14-18 07:00AM  Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer PR Newswire
Nov-09-18 07:05AM  Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results PR Newswire
07:00AM  Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting PR Newswire
Oct-21-18 06:45AM  Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress PR Newswire
Oct-17-18 09:00AM  Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-08-18 06:35PM  Leap Therapeutics to Present Data from Study Evaluating DKN-01 in Combination with KEYTRUDA® (pembrolizumab) at the European Society of Medical Oncology 2018 Congress PR Newswire -5.35%
Sep-25-18 07:00AM  Leap Therapeutics to Present at Two October Conferences PR Newswire
Aug-30-18 04:05PM  Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference PR Newswire
Aug-22-18 07:40AM  Recent Analysis Shows Leap Therapeutics, Gardner Denver, Medical Transcription Billing, CarGurus, Liberty Media, and Quorum Health Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-08-18 07:00AM  Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results GlobeNewswire
Jul-23-18 07:30AM  Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors GlobeNewswire
Jun-13-18 07:55AM  Analysis: Positioning to Benefit within Ruth's Hospitality Group, S&P Global, Shaw Communications, Leap Therapeutics, Red Hat, and Welltower Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
07:00AM  Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference GlobeNewswire
May-11-18 07:00AM  Leap Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire +9.76%
May-10-18 08:50AM  Why Leap Therapeutics (LPTX) Might Surprise This Earnings Season Zacks
Apr-16-18 09:00AM  Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting GlobeNewswire -23.10%
Mar-28-18 08:00AM  New Research Coverage Highlights Holly Energy Partners, Liberty Property Trust, Fair Isaac, 58, Cousins Properties, and Leap Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-27-18 04:05PM  Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-23-18 09:00AM  Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock GlobeNewswire
Mar-22-18 04:05PM  Leap Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-21-18 07:00AM  Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference GlobeNewswire +5.03%
Mar-14-18 05:00PM  Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting GlobeNewswire
Mar-07-18 07:00AM  Leap Therapeutics to Present at 2018 Barclays Global Healthcare Conference GlobeNewswire
Feb-06-18 07:00AM  Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-16-18 07:00AM  Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial GlobeNewswire
Nov-15-17 09:57AM  Whats Installed For Leap Therapeutics Inc (LPTX)? Simply Wall St.
07:00AM  Leap Therapeutics Announces $18 Million Private Placement Offering GlobeNewswire
Nov-13-17 07:00AM  Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial GlobeNewswire
Sep-19-17 07:00AM  Leap Therapeutics to Present at the 2017 Ladenburg Thalmann Healthcare Conference GlobeNewswire
Sep-08-17 07:00AM  Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract Cancers GlobeNewswire -5.20%
Aug-11-17 07:00AM  Leap Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire -5.02%
Jun-26-17 07:00AM  Leap Therapeutics Added to Russell Microcap® Index GlobeNewswire +6.30%
Jun-24-17 05:00PM  Could Merck and Leap Union Be the One for Keytruda? TheStreet.com
Jun-21-17 09:07AM  Leap Therapeutics Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with DKN-01 in Esophagogastric Cancer GlobeNewswire
Jun-01-17 07:00AM  Leap Therapeutics to Present at Two Investor Conferences in June GlobeNewswire
May-17-17 05:17PM  Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting GlobeNewswire
May-12-17 07:00AM  Leap Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-20-17 12:00PM  Leap Therapeutics to Present DKN-01 Clinical Data at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting GlobeNewswire
Apr-03-17 07:00AM  Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting GlobeNewswire
Mar-31-17 04:36PM  Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers GlobeNewswire +8.51%
Mar-29-17 07:00AM  Leap Therapeutics to Present at Two Investor Conferences in April GlobeNewswire
Mar-07-17 07:00AM  Leap Therapeutics to Present at 2017 Barclays Global Healthcare Conference GlobeNewswire
06:53AM  Coverage initiated on Leap Therapeutics by Ladenburg Thalmann
Mar-01-17 06:40PM  Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting GlobeNewswire
Feb-09-17 09:12AM  Leap Therapeutics To Present at 19th Annual BIO CEO & Investor Conference GlobeNewswire
Feb-03-17 08:00AM  Leap Therapeutics Presents Biomarker and Efficacy Data at the Cholangiocarcinoma Foundation 2017 Annual Meeting GlobeNewswire
Jan-28-17 01:04PM  MACROCURE LTD. Financials
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAWLOR AUGUSTINEChief Operating OfficerFeb 05Buy1.75571,428999,9994,114,804Feb 05 04:21 PM
ONSI DOUGLAS ECFO, GC, Treasurer & SecretaryFeb 05Buy1.75571,428999,9994,114,804Feb 05 04:22 PM
Mirabelli ChristopherCEO, President, ChairmanFeb 05Buy1.75571,428999,9994,114,804Feb 05 04:20 PM
HealthCare Ventures IX, L.P.10% OwnerFeb 05Buy1.75571,428999,9994,144,804Feb 05 04:19 PM